Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

FDA Approves Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma

August 20th 2020

The FDA has approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy.

Investigational Immunotherapies Elicit Unprecedented Responses in Relapsed/Refractory Myeloma

August 17th 2020

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

August 14th 2020

Nina Shah, MD, discusses ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma

August 13th 2020

In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.

Dr. Shah on Updated Efficacy of JNJ-4528 in Relapsed/Refractory Myeloma

August 12th 2020

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Dr. Shah on the Future of CAR T-Cell Therapy in Multiple Myeloma

August 12th 2020

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma.

Dr. Martin on the Safety Profile of Belantamab Mafodotin in R/R Multiple Myeloma

August 12th 2020

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. O'Donnell Discusses Ongoing Research Efforts in Multiple Myeloma

August 11th 2020

Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.

Subcutaneous Daratumumab Appears Primed to Transform Myeloma Care

August 11th 2020

A new subcutaneous formulation, daratumumab and hyaluronidase-fihj, provides similar efficacy in a more convenient and efficient regimen that is likely to change practice.

The Future of Multiple Myeloma

August 10th 2020

Targeted Treatment Options in Multiple Myeloma

August 10th 2020

Trials in Relapsed/Refractory Multiple Myeloma

August 10th 2020

Treatment Options in Relapsed/Refractory Multiple Myeloma

August 10th 2020

Options for Transplant Ineligible Patients in Multiple Myeloma

August 10th 2020

Maintenance Therapy in Multiple Myeloma

August 10th 2020

The Role of Transplant in Multiple Myeloma

August 10th 2020

Looking at GRIFFIN Trial Data

August 10th 2020

A Look at the ENDURANCE Trial

August 10th 2020

Newly Diagnosed Multiple Myeloma

August 10th 2020

Introduction to Multiple Myeloma

August 10th 2020